Günter Schneider

30PUBLICATIONS
135CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cell development, proliferation and deathCancer cell biologyCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Aug 12, 2026
Targeting PRMT5 inhibitor-induced adaptation in pancreatic cancer with the RBM39 degrader indisulam.

|Jun 10, 2026
The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma.

|Feb 25, 2026
A disease model resource reveals core principles of tissue-specific cancer evolution.

Sebastian Mueller, Niklas de Andrade Krätzig, Markus Tschurtschenthaler

|Dec 23, 2025
Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells.

Maj-Britt Paulsohn, Klara Henrike Frahnert, Denise Schlösser

|Dec 03, 2025
Proteasome inhibition as a potential therapeutic target in thymic cancer.

Satoru Okada, Louisa Benter, Leon Schrell

|Sep 16, 2025
Pan-ERBB Inhibitors Synergize With KRAS Inhibitors in Rectal Cancer.

Jonas Buchloh, Melanie Spitzner, Hauke Zimmermann

Pageof 5

Frequent Collaborators

10 joint publications

Dieter Saur

7 joint publications

Stefanie Bärthel

6 joint publications

Roland Rad

5 joint publications

Katja Steiger